FDA OKs new drug to treat all forms of hepatitis C

By  | 

UDATED (AP) -- U.S. regulators have approved another drug to treat all forms of hepatitis C that works in as little as eight weeks.

AbbVie's drug, Mavyret , was approved Thursday by the Food and Drug Administration for patients without significant cirrhosis who haven't been treated previously for the liver-destroying virus, plus those with a form of hepatitis who were not cured by a prior treatment.

Mavyret joins two other AbbVie hepatitis C drugs, one from Merck and several from Gilead on the market.

The list price without insurance will range from $26,400 for eight weeks' treatment to $52,800 for 16 weeks' treatment.

Hepatitis C affects at least 2.7 million people in U.S. The virus develops slowly over decades and many people don't realize they are infected until signs of liver damage emerge.



 
The comment sections of our web set are designed for thoughtful, intelligent conversation and debate. We want to hear from the viewers but we are not obligated to post comments we feel inappropriate or violate our guidelines. Here are some of the criteria you should follow when posting comments:

Comments cannot be profane or vulgar. Children and families visit this site. We will delete comments that use profanity or cross the lines of good taste.

We will delete all comments using hate speech. Slurs, stereotypes and violent talk aren’t welcome on our web site.

Comments should not attack other readers personally.

We will delete comments we deem offensive, in bad taste, or out of bounds. We are not obligated to post comments that are rude or insensitive.

We do not edit user-submitted comments.

As a host WEAU 13 News welcomes a wide spectrum of opinions. However, we have a responsibility to all our readers to try to keep our comment section fair and decent. For that reason WEAU 13 News reserves the right to not post or to remove any comment.
powered by Disqus